The present and future of gene profiling in breast cancer

Espinosa, Enrique; Gámez‐Pozo, Angelo; Sánchez‐Navarro, Iker; Pinto, Álvaro; Castaneda, CA; Ciruelos, Eva; Feliú, Jaime; Vara, Juan Ángel Fresno

doi:10.1007/s10555-011-9327-7

Cited by 16 publications

(16 citation statements)

References 48 publications

(49 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since the description of a 70-gene profile in 2002, this and other gene signatures, such as Recurrence Score, have made their way into the clinic very rapidly, because they provide clinically useful information (2).…”

Section: Introductionmentioning

confidence: 99%

Combined Label-Free Quantitative Proteomics and microRNA Expression Analysis of Breast Cancer Unravel Molecular Differences with Clinical Implications

et al. 2015

View full text Add to dashboard Cite

Better knowledge of the biology of breast cancer has allowed the use of new targeted therapies, leading to improved outcome. High-throughput technologies allow deepening into the molecular architecture of breast cancer, integrating different levels of information, which is important if it helps in making clinical decisions. microRNA (miRNA) and protein expression profiles were obtained from 71 estrogen receptor-positive (ER þ ) and 25 triple-negative breast cancer (TNBC) samples. RNA and proteins obtained from formalin-fixed, paraffin-embedded tumors were analyzed by RT-qPCR and LC/MS-MS, respectively. We applied probabilistic graphical models representing complex biologic systems as networks, confirming that ER þ and TNBC subtypes are distinct biologic entities. The integration of miRNA and protein expression data unravels molecular processes that can be related to differences in the genesis and clinical evolution of these types of breast cancer. Our results confirm that TNBC has a unique metabolic profile that may be exploited for therapeutic intervention. Cancer Res; 75(11); 2243-53. Ó2015 AACR.

show abstract

Section: Introductionmentioning

confidence: 99%

Combined Label-Free Quantitative Proteomics and microRNA Expression Analysis of Breast Cancer Unravel Molecular Differences with Clinical Implications

et al. 2015

View full text Add to dashboard Cite

show abstract

“…The decision of whether to administer adjuvant chemotherapy to patients with breast cancer is based on the estimated risk of recurrence [5]. For this decision, oncologists may use algorithms based on clinical-pathological criteria.…”

Section: Introductionmentioning

confidence: 99%

“…For this decision, oncologists may use algorithms based on clinical-pathological criteria. Tumor recurrence can be predicted by various factors: lymph node involvement, tumor size, histology subtype and grade, vascular and lymphatic invasion, proliferation markers, hormone receptors and human epidermal growth factor receptor 2 (HER2) overexpression [4,5].…”

Section: Introductionmentioning

confidence: 99%

“…In patients suffering from breast cancer, gene expression profiling facilitates estimates of the risk of tumor recurrence in those patients with early stage disease [5]. The most widely used platforms are MammaPrint ® and Oncotype DX ® [7].…”

Section: Introductionmentioning

confidence: 99%

“…The major drawback of Oncotype DX ® is that an intermediate risk of recurrence makes therapeutic decisions more complex, as the benefit of chemotherapy in these patients is doubtful [5]. Nevertheless, both tools have been shown to be clinically useful in the prognosis of the risk of cancer recurrence [8,[9][10][11][12][13][14][15][16].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Genomic profile of breast cancer: cost–effectiveness analysis from the Spanish National Healthcare System perspective

Seguí

Crespo

Cortés

et al. 2014

Expert Review of Pharmacoeconomics & Outcomes Research

View full text Add to dashboard Cite

show abstract

Perinodal fibrosis developed after ultrasonography‐guided core‐needle biopsy of a contrast‐enhanced ultrasound‐detected sentinel axillary node interferes with subsequent surgical sentinel node dissection

Serquiz

Moro

Menossi

et al. 2019

J of Clinical Ultrasound

View full text Add to dashboard Cite

Objective To evaluate perinodal fibrosis after 14‐gauge staging core‐needle biopsy (CNB) of the axillary sentinel lymph node (SLN) identified using contrast‐enhanced ultrasonography (CEUS) and its interference with subsequent surgical SLN dissection in breast cancer patients. Methods Frequencies or means of main clinical, sonographic, pathological, and surgical characteristics were calculated. We also compared patient groups with and without perinodal pathological fibrosis. Results Forty‐eight patients who underwent CEUS + CNB and axillary surgery were eligible for this cross‐sectional study. Axillary surgical specimens showed perinodal fibrosis in 9/48 (18.7%) patients. Interference with SLN dissection was reported in 4/48 (8.3%) patients (two hematomas, three abnormal palpation findings, and four difficult dissections). The overall surgical detection rate of SLN was 43/48 (89.6%). In the majority of cases, perinodal fibrosis was described as moderate (4/9 [44.4%]) or severe (4/9 [44.4%]). The mean time elapsed between CEUS + CNB and axillary dissection was shorter in patients with perinodal fibrosis (P = .04). Interference with SLN dissection was only reported in patients with perinodal fibrosis (P < .001). Surgical SLN detection was successful in all nine cases in which perinodal pathological fibrosis or interference with SLN dissection was reported. Conclusion Perinodal fibrosis may impair the surgical SLN dissection in early stage breast cancer patients who were staged using CEUS + CNB using a14‐gauge needle.

show abstract

The present and future of gene profiling in breast cancer

Cited by 16 publications

References 48 publications

Combined Label-Free Quantitative Proteomics and microRNA Expression Analysis of Breast Cancer Unravel Molecular Differences with Clinical Implications

Combined Label-Free Quantitative Proteomics and microRNA Expression Analysis of Breast Cancer Unravel Molecular Differences with Clinical Implications

Genomic profile of breast cancer: cost–effectiveness analysis from the Spanish National Healthcare System perspective

Perinodal fibrosis developed after ultrasonography‐guided core‐needle biopsy of a contrast‐enhanced ultrasound‐detected sentinel axillary node interferes with subsequent surgical sentinel node dissection

Contact Info

Product

Resources

About